title: Are pentraxin 3 and transsignaling early markers for immunologic injury severity in polytrauma? A pilot study.
abstract: BACKGROUND
  Inflammatory-related conditions and organ failure (OF) lead to late trauma mortality. Cytokine profiles can predict adverse events and mortality, potentially guiding treatment strategies (damage control surgery versus early total care). However, the specific cytokines to predict the clinical course in polytraumatized patients are not fully identified.
  
  
  OBJECTIVE
  We investigated the early pentraxin 3 (PTX3), IL-6, soluble IL-6 receptor (sIL-6R), and transsignaling ratio (TSR) in polytraumatized patients to estimate immunologic injury severity and predict OF and survival.
  
  
  METHODS
  We prospectively followed 58 patients with severe polytrauma, six patients with minor trauma, and 10 healthy volunteers. The mean Injury Severity Score (ISS) was 43 points and the mean Hannover Polytrauma Score (PTS) was 59 points, with a consequently high mortality rate (30%). Twenty-seven of the 58 polytraumatized patients (46%) developed OF, 67% systemic inflammatory response syndrome, and 38% sepsis.
  
  
  RESULTS
  Mean sIL-6R concentrations in polytrauma initially were low. Mean PTX3 concentrations were high and peaked at 24 hours. The mean TSR peaked at 6 hours; at that time, the mean value was higher for nonsurvivors. PTX3 concentrations at admission were associated with injury severity calculated by ISS and PTS. Higher PTX3 serum concentrations 24 hours after admission correlated with lower probability for survival.
  
  
  CONCLUSIONS
  PTX3, sIL-6R, and TSR were early markers for posttraumatic inflammatory status, OF, injury severity, and TSR for survival after polytrauma. The temporal profile of PTX3 and TSR might be used to anticipate the total injury severity and the clinical course and thereby guide decision making in polytraumatized patients.
authors.affiliation: Center for Musculoskeletal Surgery and Julius Wolff Institute, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. christian.kleber@charite.de
authors.forename: Christian
authors.initials: C
authors.lastname: Kleber
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Becker
authors.forename: Katharina
authors.initials: K
authors.lastname: Schmidt-Bleek
authors.forename: Klaus D
authors.initials: KD
authors.lastname: Schaser
authors.forename: Norbert P
authors.initials: NP
authors.lastname: Haas
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000209:etiology; D015601:Injury Severity Score; D015850:Interleukin-6 / Q000097:blood*; D009104:Multiple Trauma / Q000097:blood* / Q000150:complications; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011446:Prospective Studies; D019947:Receptors, Interleukin-6 / Q000097:blood*; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood* / Q000209:etiology; D000099153:Pentraxins
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D000683:Serum Amyloid P-Component; D000099153:Pentraxins